サンプル依頼リスト カート
  • English
  • Korean
表紙：再発性多形性膠芽腫（GBM）の臨床試験分析：試験フェーズ、試験ステータス、試験回数、エンドポイント、ステータス、スポンサータイプ、主要国別-2022年最新版
市場調査レポート
商品コード
1109524

再発性多形性膠芽腫（GBM）の臨床試験分析：試験フェーズ、試験ステータス、試験回数、エンドポイント、ステータス、スポンサータイプ、主要国別-2022年最新版

Recurrent Glioblastoma Multiforme (GBM) Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update
出版日: | 発行: GlobalData | ページ情報: 英文 548 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
再発性多形性膠芽腫（GBM）の臨床試験分析：試験フェーズ、試験ステータス、試験回数、エンドポイント、ステータス、スポンサータイプ、主要国別-2022年最新版
出版日: 2022年05月24日
発行: GlobalData
ページ情報: 英文 548 Pages
納期: 即納可能 即納可能とは
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の再発性多形性膠芽腫（GBM）市場について調査分析し、投資に関する主要なビジネス戦略、時間とコストを削減するのに役立つ臨床試験の実施に適した場所、主要なビジネスチャンスの特定に役立つ世界の臨床試験市場のトップレベルの分析等に関する情報を提供しています。

目次

目次

  • 報告ガイダンス
  • GlobalDataの臨床試験調査レポートの範囲
  • 臨床試験：地域別
  • 臨床試験と平均登録者数：国別
  • 臨床試験：G7諸国別-腫瘍学の臨床試験における再発性多形性膠芽腫（GBM）の割合
  • 臨床試験：G7諸国におけるフェーズ別
  • 臨床試験：G7諸国における試験ステータス別
  • 臨床試験：E7諸国別-腫瘍学の臨床試験における再発性多形性膠芽腫（GBM）の割合
  • 臨床試験：E7諸国におけるフェーズ別
  • 臨床試験：E7諸国における試験ステータス別
  • 臨床試験：フェーズ別
  • 進行中の試験：フェーズ別
  • 臨床試験：試験ステータス別
  • 臨床試験：エンドポイントステータス別
  • 一定期間にわたって採用された被験者
  • 臨床試験：スポンサータイプ別
  • 著名なスポンサー
  • 再発性多形性膠芽腫（GBM）治療の臨床試験に参加している主要企業
  • 著名な薬
  • 臨床試験プロファイルのスナップショット

付録

  • 略語
  • 定義
  • 調査手法
  • 2次調査
  • GlobalDataについて
  • お問い合わせ
  • 免責事項
  • 情報源
図表

List of Tables

List of Tables

  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Region, 2022*
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2022*
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2022*
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2022*
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Europe, Top Five Countries, 2022*
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, North America, Top Countries, 2022*
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2022*
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Central and South America, Top Countries, 2022*
  • Proportion of Recurrent Glioblastoma Multiforme (GBM) to Oncology Clinical Trials, G7 Countries (%), 2022*
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics, G7 Countries, Clinical Trials by Phase, 2022*
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2022*
  • Proportion of Recurrent Glioblastoma Multiforme (GBM) to Oncology Clinical Trials, E7 Countries (%), 2022*
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics, E7 Countries, Clinical Trials by Phase, 2022*
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2022*
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Phase, 2022*
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials In Progress by Phase 2022*
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Trial Status, 2022*
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, by End Point Status, 2022*
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2017-2021
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2022*
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Key Sponsors, 2022*
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2022*
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2022*

List of Figures

List of Figures

  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Region (%), 2022*
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2022*
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2022*
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2022*
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2022*
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, North America, Top Countries (%), 2022*
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2022*
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2022*
  • Proportion of Recurrent Glioblastoma Multiforme (GBM) to Oncology Clinical Trials, G7 Countries (%), 2022*
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics, G7 Countries, Clinical Trials by Phase, 2022*
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2022*
  • Proportion of Recurrent Glioblastoma Multiforme (GBM) to Oncology Clinical Trials, E7 Countries (%), 2022*
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics, E7 Countries, Clinical Trials by Phase, 2022*
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2022*
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Phase (%), 2022*
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials In Progress by Phase, 2022*
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Trial Status, 2022*
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, by End Point Status, 2022*
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2017-2021
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2022*
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Key Sponsors, 2022*
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2022*
  • Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2022*
  • GlobalData Methodology
目次
Product Code: GDHC6880CTIDB

GlobalData's clinical trial report, "Recurrent Glioblastoma Multiforme (GBM) Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update" provides an overview of Recurrent Glioblastoma Multiforme (GBM) Clinical trials scenario. This report provides top line data relating to the clinical trials on Recurrent Glioblastoma Multiforme (GBM). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

  • Report Guidance
  • GlobalData Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Clinical Trials by G7 Countries: Proportion of Recurrent Glioblastoma Multiforme (GBM) to Oncology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Recurrent Glioblastoma Multiforme (GBM) to Oncology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profile Snapshots

Appendix

  • Abbreviations
  • Definitions
  • Research Methodology
  • Secondary Research
  • About GlobalData
  • Contact Us
  • Disclaimer
  • Source